Spectrum Pharmaceuticals Acquires From Indena Worldwide Rights to Ortataxel, a Phase 2 Third Generation Taxane

Spectrum Pharmaceuticals, Inc., and Indena S.p.A. announced the signature of a worldwide license agreement for ortataxel, a third-generation taxane classified as a new chemical entity (NCE) that has demonstrated clinical activity in taxane-refractory tumors.
CNN Money